1
/
of
1
Olmesar (Olmesartan)
Olmesar (Olmesartan)
Regular price
₱625.00 PHP
Regular price
Sale price
₱625.00 PHP
Unit price
₱20.83 each
Taxes included.
Quantity
Couldn't load pickup availability
Olmesartan medoxomil, marketed as Olmesar, is a selective angiotensin II receptor antagonist (ARB) belonging to the class of antihypertensive medications. This potent prescription drug is specifically designed to manage hypertension by blocking AT₁ receptors, thereby preventing angiotensin II from constricting blood vessels and increasing vascular resistance. The mechanism of action allows olmesartan to produce a sustained, dose-dependent reduction in both systolic and diastolic blood pressure, making it an effective option for once-daily dosing regimens.
Olmesar is primarily indicated for the treatment of essential hypertension in adult and pediatric populations over six years of age. Clinical evidence supports its use as a monotherapy or in combination with other antihypertensive agents such as thiazide diuretics or calcium channel blockers to achieve optimal blood pressure control. The drug works by relaxing vascular smooth muscle, reducing peripheral vascular resistance, and facilitating improved blood flow, thereby decreasing the overall workload on the cardiovascular system.
Beyond blood pressure reduction, olmesartan offers significant cardiovascular protective benefits by reducing the long-term risk of myocardial infarction and cerebrovascular events in hypertensive patients. Additionally, olmesartan provides renal protection in patients with concurrent hypertension and diabetes mellitus, helping to slow the progression of diabetic nephropathy and preserve glomerular filtration rate. The medication's tolerability profile is generally favorable, with most patients experiencing minimal adverse effects during long-term therapy.
Olmesar is widely recognized in international hypertension management guidelines as a first-line or adjunctive therapeutic option for patients with resistant or difficult-to-control hypertension. Its strong pharmacological efficacy, extended half-life enabling once-daily administration, and favorable safety profile make it a preferred choice among healthcare providers managing cardiovascular risk in hypertensive populations.
Olmesar is primarily indicated for the treatment of essential hypertension in adult and pediatric populations over six years of age. Clinical evidence supports its use as a monotherapy or in combination with other antihypertensive agents such as thiazide diuretics or calcium channel blockers to achieve optimal blood pressure control. The drug works by relaxing vascular smooth muscle, reducing peripheral vascular resistance, and facilitating improved blood flow, thereby decreasing the overall workload on the cardiovascular system.
Beyond blood pressure reduction, olmesartan offers significant cardiovascular protective benefits by reducing the long-term risk of myocardial infarction and cerebrovascular events in hypertensive patients. Additionally, olmesartan provides renal protection in patients with concurrent hypertension and diabetes mellitus, helping to slow the progression of diabetic nephropathy and preserve glomerular filtration rate. The medication's tolerability profile is generally favorable, with most patients experiencing minimal adverse effects during long-term therapy.
Olmesar is widely recognized in international hypertension management guidelines as a first-line or adjunctive therapeutic option for patients with resistant or difficult-to-control hypertension. Its strong pharmacological efficacy, extended half-life enabling once-daily administration, and favorable safety profile make it a preferred choice among healthcare providers managing cardiovascular risk in hypertensive populations.
Share
